Glaucoma HFA / OCT Specificity Study

Each visit consists of optical coherence tomography (OCT) scanning (4 scans ) and two HFA
(Humphrey Field Analyzer) visual fields of the study eye only.

Inclusion Criteria:

- Adult males or females 40 to 80 years old

- Able and willing to attend the required study visits

- Able and willing to provide consent and follow study instructions in English

- A diagnosis by the Principal Investigator or co-investigator of glaucoma,
pre-perimetric glaucoma or glaucoma suspect

- Subjects must have experience in threshold automated perimetry, having performed a
previous SITA (Swedish Interactive Thresholding Algorithm) threshold test within one
year of enrolling to the study

- Ability to fixate that allows obtaining acceptable visual fields and OCT scans in the
study eye

Exclusion Criteria:

- • Best-corrected visual acuity less than 20/40 (study eye only) on a Snellen chart or
on a Snellen equivalent acuity chart

- Spherical refraction outside -12.00 to +5.00 diopters (D) or cylinder correction
outside 3.00 D (study eye only)

- Amblyopia (either eye)

- Narrow irido-corneal angles or a diagnosis of narrow angle glaucoma

- Previous or current eye disease in the study eye, serious eye trauma or
intraocular surgery (except cataracts with lens implants), or the presence of
ocular findings that could affect the visual field, other than glaucoma

- Cataract surgery in the study eye within six (6) months of first visit

- Dx of any optic neuropathy other than glaucoma

- Vitreoretinal traction or epiretinal membrane in the study eye

- Diagnosis or history of any systemic disease / condition / treatment which is
likely to affect the visual field outcome in the Study Eye other than glaucoma

- History of diabetes, leukemia, AIDS, uncontrolled systemic high blood pressure,
dementia or multiple sclerosis

- Any disease that is likely to progress within the 3 month time period that might
have visual field implications

- A life threatening or debilitating disease

- Participation in any study involving a non-FDA approved investigational drug
(IND) within the past month, or ongoing participation in a study with a non-FDA
approved or cleared investigational device (IDE)

- Concomitant use of hydrochloroquine and/or chloroquine